Incidence of major adverse cardiovascular events with genotype test guided antiplatelet treatment strategy after percutaneous coronary intervention

S. Ramesha, S. Socrates, M.A. Rajasekaran, N. Senguttuvan

Sri Ramachandra Institute Higher Education & Research (SRIHER), Porur, Chennai, 600116, India
Sree Balaji Medical College Hospital, Chromepet, Chennai, 600044, India

1. Introduction

Antiplatelets are the cornerstone in preventing major adverse cardiac events (MACE) post percutaneous coronary intervention (PCI). Clopidogrel is a P2Y12 receptor antagonist which, upon administration, is metabolized to its active form by hepatic cytochrome P450 system. Platelet inhibition level and inhibition rate of clopidogrel are dose dependent. Subgroup enzymes CYP2C19 and CYP3A4/5 of cytochrome P450 enzymes family are most commonly involved in clopidogrel metabolism. Genetic polymorphisms in CYP2C19 impair clopidogrel metabolism in healthy volunteers and in patients. This poor metabolizer phenotype has also been associated with an increased risk of cardiovascular (CV) events. The CYP2C19*2 genetic variant, 681 G > A (rs4244285), was identified as a major determinant of prognosis in young patients who received clopidogrel treatment after myocardial infarction (MI).

Furthermore, patients carrying any two CYP2C19 loss-of-function alleles [*2, *3 (rs4986893), *4 (rs28399504), or *5 (rs56337013)] had higher rates of CV events than patients lacking these alleles. Based on the variable pharmacodynamic response to clopidogrel, patients have been classified as non-responders, poor responders or resistant to clopidogrel. In addition, factors such as age, diabetes, renal failure, and cardiac failure also influence clopidogrel response. Evidence shows that the prevalence of clopidogrel resistance in India is in line with the global scenario. Based on these findings, Ray, in his review article, suggested the use of higher loading doses of clopidogrel (600 mg) or more potent P2Y12 receptor agents (e.g. prasugrel, ticagrelor, cangrelor) as strategies to overcome clopidogrel resistance.

Switching between P2Y12 receptor antagonists is frequently seen in clinical practice as prasugrel and ticagrelor used early-on after a PCI are de-escalated to clopidogrel maintenance to decrease the risk of bleeding and reduce treatment costs. A line of
evidence shows that CYP2C19 genotyping to guide this de-escalation is effective in optimizing the clinical outcomes in patients undergoing PCI.16–18 The present study aimed to evaluate the efficiency of genotype test-guided antiplatelet therapy (de-escalating ticagrelor to clopidogrel) on major adverse cardiac outcomes (MACE) in patients undergoing PCI.

2. Methods

2.1. Patient selection and recruitment

This was a non-randomized prospective study conducted at a tertiary-care teaching hospital in India. The study protocol was approved by the hospital ethics committee. Written informed consent was obtained from all study participants before their participation in the trial.

Eligible patients were aged 18 years and above, had undergone PCI for acute coronary syndrome as well as chronic coronary syndrome and required antiplatelet therapy as a part of therapeutic management. Patients were excluded if they presented with: (i) history of using clopidogrel, nonsteroidal anti-inflammatory drugs, and anticoagulants. (ii) history of coronary artery bypass surgery (CABG); (iii) history of using clopidogrel, nonsteroidal anti-inflammatory drugs, and anticoagulants.

2.2. Study procedure

As per the hospital protocol, and in accordance with the current clinical practice guidelines, all the patients were given ticagrelor and aspirin after the procedure. Principal investigator/study coordinator discussed the implications of pharmacogenetic testing and study objectives with the potential patients, and requested them to participate in the study. Consenting patients provided a written informed consent to participate in the study, and study-specific screening was performed on these patients. In all, 151 patients were recruited from this single study center.

At index procedure, saliva samples were collected from the study participants for genotyping CYP2C19*2 and CYP2C19*3 variations using the Xcode life sciences saliva collection kit19 and the were sent to ‘The Xcode Life Sciences Private Limited’ laboratory for analysis. The Principal investigator/study coordinator reviewed the results and according to their CYP2C19*2 and CYP2C19*3 variations, categorized the patients as ‘normal’ (GG, GC), “intermediate” (AG), or “poor” metabolizes [homozygous variant AA]. Based on pharmacogenetic testing, antiplatelets were switched to double-dose and single-dose clopidogrel in intermediate and normal metabolizes, respectively. According to the study protocol, patients categorized as normal metabolizes were prescribed therapeutic doses of clopidogrel, and those categorized as intermediate metabolizes were prescribed double the therapeutic dose of clopidogrel. All poor metabolizes were continued on ticagrelor. In patients who were switched from ticagrelor to clopidogrel was given 300 mg of loading dose of clopidogrel 12 h after last dose of ticagrelor. Patients were followed-up for a period of six months. Patients were evaluated during their scheduled clinic visits and were also advised to contact the study personnel if they experienced any adverse events during the study period.

2.3. Study endpoints

The primary clinical outcome was MACE, defined as a composite of CV death, nonfatal MI, definite/probable stent thrombosis (ST), revascularization, stroke or transient ischemic attack (TIA), and clinically significant bleeding event.20,21

2.4. Statistical analysis

Continuous and quantitative variables were summarized using descriptive statistics. Categorical data were presented as frequency count (n) and percentages (%). All statistical analyses were performed using SAS (version 9.4).

3. Results

3.1. Patient demography and baseline characteristics

In all, 176 patients were screened and 151 patients were recruited. All enrolled subjects completed the study, which included 128 (84.8%) males and 23 (15.2%) females. Mean age of the male and female population was 54.59 ± 11 years and 55.9 ± 11.5 years, respectively. The clinical features and risk factors are presented in Table 1. Diabetes (29.1%) and hypertension (25.2%) were the most commonly seen comorbidities in the study population. Many patients (39.1%) presented with anterior wall myocardial infarction (AWMI), and inferior wall myocardial infarction (IWMI) (22.5%).

Based on the genotyping data of CYP2C19*2 and CYP2C19*3 variations, over half of the patients were categorized as ‘intermediate’ (78, 51.65%), followed by ‘normal' (43, 28.48%) and ‘poor’ (30, 19.87%). Similar trend was observed in the male and female subgroups (Table 2).

3.2. Major adverse cardiac outcomes

No major bleeding episodes were reported in all patients (151) during the study period and follow-up. Three patients (2.0%) presented with MI, as was confirmed by elevated cardiac troponin levels. Of these three, one patient on ticagrelor presented with probable stent thrombosis and was found to be non-compliant to the antiplatelet treatment. The other two patients were on clopidogrel and had lesions in the non-culprit vessels with patented stents. All these patients underwent coronary angiography (CAG) to confirm the same.

4. Discussion

Clinical outcomes of genotype-guided, de-escalation of antiplatelet therapy have not been well reported in Indian patients. Thus, in our study we attempted to find an incidence of clopidogrel resistance in the south Indian population with genotyping. The present study also attempted to minimize the occurrence of MACE due to clopidogrel resistance in patients undergoing PCI by genotype-guided antiplatelet therapy. In our study, 19.87% of patients found to be poor metabolizers. This was in line with the previous reports that indicated clopidogrel resistance rate to be between 5% and 56% in a similar population.22 As it has been reported that adverse CV events occur frequently in patients with clopidogrel resistance, our study was designed to treat poor metabolizers with therapeutic doses of newer antiplatelet agent, ticagrelor,23 and the intermediate metabolizes with double-dose clopidogrel. This strategy is supported by the CURRENT OASIS 7 study24 and the VASP-02 study,25 which reported significantly lower rate of CV death, MI and stroke with this treatment regimen. After one-month follow-up, the CURRENT OASIS 7 study reported MACE of 3.9% in the double-dose group vs. 4.3% in the normal dose group. VASP-02 study reported no MACE in any of the groups. However, 19% of minor bleeding episodes in the double-dose (150 mg/day) group, vs. 22.6% in the normal dose (75 mg/day) group after one-month follow-up were reported.25
Three out of 151 patients (1.5%) had MACE during six months of follow-up in our study. Of these three patients, one subject was found to be non-compliant with the antiplatelet therapy and had stent thrombosis. The other two subjects developed thrombotic lesions in the non-culprit vessels with patented stents. Our study did not report any major bleeding complications.

Genotyping for CYP2C19 variations in patients undergoing PCI and the genotyping-guided therapeutic intervention strategy presented to be beneficial in minimizing MACE after coronary intervention.

5. Limitations

The present study is a single center, non-randomized study with a limited sample size and follow-up of 6 months.

Sources of funding

None.

Declaration of competing interest

All authors have none to declare.

References

1. Savi P, Herbert JM. Clopidogrel and ticlopidine: P2Y12 adenosine diphosphate receptor antagonists for the prevention of atherothrombosis. Semin Thromb Haemost. 2005;31(2):174–183.
2. Savic M, Hauert J, Bachmann F, et al. Clopidogrel loading dose regimens: kinetic profile of pharmacodynamic response in healthy subjects. Semin Thromb Hemost. 1999;25:15–19.
3. Brandt JT, Close SL, Iturria SJ, et al. Common polymorphisms of CYP2C19 and CYP2C9 affect the pharmacokinetic and pharmacodynamic response to clopidogrel but not prasugrel. J Thromb Haemostasis. 2007;5(12):2429–2436.
4. Simon T, Verstuyft C, Mary-Krause M, et al. Genetic determinants of response to clopidogrel and cardiovascular events. N Engl J Med. 2009;360(4):363–375.
5. Kazui M, Nishiya Y, Ishizuka T, et al. Identification of the human cytochrome P450 enzymes involved in the two oxidative steps in the bioactivation of clopidogrel to its pharmacologically active metabolite. Drug Metab Dispos. 2010;38(1):92–99.
6. Collet JP, Hulot JS, Pena A, et al. Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort study. Lancet. 2009;373(9660):309–317.
7. Geisler T, Schaeffeler E, Dippon J, et al. CYP2C19 and nongenetic factors predict poor responsiveness to clopidogrel loading doses after coronary stent implantation. Pharmacogenomics. 2008;9(9):1251–1259.

What is already Known?

Genetic polymorphisms of CYP2C19 impairs clopidogrel metabolism and has been associated with an increased risk of CV events.

What this study adds?

Genotyping for CYP2C19 variations in patients undergoing PCI and subsequent drug selection helps in reducing MACE after coronary intervention.

Acknowledgements

The authors wish to thank XCode Life Sciences Private Limited, Chennai, for performing the genotyping from saliva samples of the study participants and Sree Balaji Medical College Hospital, Chromepet, Chennai for providing all the facilities to conduct this clinical study.

Table 1

| Characteristics         | Total n = 151 | %     |
|-------------------------|--------------|-------|
| Coronary risk factors   |              |       |
| Diabetes                | 47           | 31.1  |
| Hypertension            | 38           | 25.2  |
| Smoker                  | 47           | 31.1  |
| Alcohol use             | 44           | 29.1  |
| Positive family history | 12           | 7.9   |
| Presentation            |              |       |
| AWMI                    | 59           | 39.1  |
| IWMI                    | 34           | 22.5  |
| NSTEMI                  | 7            | 4.6   |
| Atypical angina         | 3            | 2.0   |
| Unstable angina         | 2            | 1.3   |
| Chronic stable angina   | 11           | 7.3   |
| IHD                     | 7            | 4.6   |
| CAD                     | 1            | 0.7   |
| Coronary angiography    |              |       |
| SVD                     | 93           | 61.6  |
| DVD                     | 26           | 17.2  |
| TVD                     | 4            | 2.6   |
| LMCA disease            | 2            | 1.3   |
| LV function             |              |       |
| Normal                  | 41           | 27.2  |
| LV dysfunction          | 82           | 54.3  |

AWMI, anterior wall myocardial infarction; IWMI, inferior wall myocardial infarction; NSTEMI, non-ST segment elevation myocardial infarction; IHD, ischemic heart disease; CAD, coronary artery disease; SVD, small vessel disease; DVD, double vessel disease; TVD, triple vessel disease; LMCA, left main coronary artery; LV, left ventricular.

Table 2

Categorisation of Patients based on CYP2C19*2 and CYP2C19*3 Variations.

| Gender (n) | Category (n) | Age Mean ± SD | %CV | Age Range |
|------------|--------------|---------------|-----|-----------|
| Overall (151) | Normal (43) | 55.8 ± 1107 | 19.82 | 29–80 |
|            | Intermediate (78) | 54.61 ± 12.41 | 22.74 | 24–86 |
|            | Poor (30) | 53.73 ± 10.56 | 19.66 | 36–75 |
| Male (128)  | Normal (38) | 55.68 ± 11.65 | 20.93 | 29–80 |
|            | Intermediate (65) | 54.63 ± 12.56 | 22.09 | 24–86 |
|            | Poor (25) | 52.84 ± 9.53 | 18.03 | 36–73 |
| Female (23) | Normal (5) | 57 ± 5.34 | 9.37 | 53–65 |
|            | Intermediate (13) | 54.54 ± 12.17 | 22.31 | 40–75 |
|            | Poor (5) | 58.2 ± 15.3 | 26.29 | 42–75 |

CYP2C19, Cytochrome P450 2C19.
8. Shuldiner AR, O’Connell JR, Bleden KP, et al. Association of cytochrome P450 2C19 genotype with the anti-platelet effect and clinical efficacy of clopidogrel therapy. *J Am Med Assoc.* 2009;302(8):849–857.

9. Guha S, Sardar P, Guha P, et al. Dual antiplatelet drug resistance in patients with acute coronary syndrome. *Indian Heart J.* 2009;61(1):68–73.

10. Kar R, Meena A, Yadav BK, et al. Clopidogrel resistance in North Indian patients of coronary artery disease and lack of its association with platelet ADP receptors P2Y1 and P2Y12 gene polymorphisms. *Platelets.* 2013;24(4):297–302.

11. Kumar S, Saran RK, Puri A, et al. Profile and prevalence of clopidogrel resistance in patients of acute coronary syndrome. *Indian Heart J.* 2007;59(2):152–156.

12. Ray S. Clopidogrel resistance: the way forward. *Indian Heart J.* 2014;66(5):530–534.

13. Angiolillo DJ, Rollini F, Storey RF, et al. International expert consensus on switching platelet P2Y12 receptor—inhbiting therapies. *Circulation.* 2017;136(20):1955–1975.

14. Rollini F, Franchi F, Angiolillo DJ. Switching P2Y 12-receptor inhibitors in patients with coronary artery disease. *Nat Rev Cardiol.* 2016;13(1):11–27.

15. Alexopoulos D, Xanthopoulou I, Deftereos S, et al. In-hospital switching of oral P2Y12 inhibitor treatment in patients with acute coronary syndrome undergoing percutaneous coronary intervention: prevalence, predictors and short-term outcome. *Am Heart J.* 2014;167(1):68–76.

16. Martin J, Williams AK, Klein MD, et al. Frequency and clinical outcomes of CYP2C19 genotype-guided escalation and de-escalation of antiplatelet therapy in a real-world clinical setting. *Genet Med.* 2019;22(1):160–169.

17. Cavallari LH, Franchi F, Rollini F, et al. Clinical implementation of rapid CYP2C19 genotyping to guide antiplatelet therapy after percutaneous coronary intervention. *J Transl Med.* 2018;16(1):92.

18. Claassens DM, Vos GJ, Bergmeijer TO, et al. A genotype-guided strategy for oral P2Y12 inhibitors in primary PCI. *N Engl J Med.* 2019;381(17):1621–1631.

19. Xcode life sciences saliva collection kit. Sourced at: https://isohelix.com/products/genefix-saliva-dna-collection-device/ (Accessed on May 06, 2020).

20. Hicks KA, Mahaffey KW, Mehran R, et al. 2017 cardiovascular and stroke endpoint definitions for clinical trials. *J Am Coll Cardiol.* 2018;71(9):1021–1034.

21. Margolis KL, Mahady SE, Nelson MR, et al. Development of a standardized definition for clinically significant bleeding in the ASPirin in Reducing Events in the Elderly (ASPREE) trial. *Contemp Clin Trials Commun.* 2018;11:30–36.

22. Serebruany VL, Steinhubl SR, Berger PB, et al. Variability in platelet responsiveness to clopidogrel among 544 individuals. *J Am Coll Cardiol.* 2005;45(2):246–251.

23. Patrano C, Coller B, FitzGerald GA, et al. Platelet active drugs: the relationships among dose, effectiveness, and side effects: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. *Chest.* 2004;126(3):2345–2645.

24. Mehta SR, Tanguay JF, Eikelboom JW, et al. Double-dose versus standard-dose clopidogrel and high-dose versus low-dose aspirin in individuals undergoing percutaneous coronary intervention for acute coronary syndromes (CURRENT-OASIS 7): a randomised factorial trial. *Lancet.* 2016;377(9768):1233–1243.

25. Aleil B, Jacquemin L, De Poli F, et al. Clopidogrel 150 mg/day to overcome low responsiveness in patients undergoing elective percutaneous coronary intervention: results from the VASP-02 (Vasodilator-Stimulated Phosphoprotein-02) randomized study. *J Am Coll Cardiol Intv.* 2008;1(8):631–638.